Long-term surgical outcomes of porous polyethylene orbital implants: a review of 314 cases

Su-Kyung Jung, Won-Kyung Cho, Ji-Sun Paik, Suk-Woo Yang

ABSTRACT

Purpose This study reports on the long-term surgical outcomes after the insertion of porous Medpor orbital implants into anophthalmic sockets.

Methods A retrospective chart review of 314 eyes from 314 patients who underwent evisceration, enucleation and secondary procedures using Medpor orbital implants was completed focusing on implant-associated complications and their corrective methods as surgical outcomes.

Results The mean follow-up was 50 months (range 6–107 months). The most common complication was blepharoptosis (n=33, 10.5%). Other postoperative complications were exposure (n=14, 4.5%) and implant infection (n=3, 1%). The complications were successfully managed by surgical repair and/or conservative care.

Conclusion Using Medpor resulted in similar surgical outcomes, in terms of the types and frequencies of complications, as other kinds of porous orbital implants.

Medpor (Porex Surgical, Inc, College Park, Georgia, USA) is a porous form of polyethylene that is now widely used with hydroxyapatite to compensate for the loss of volume in an anophthalmic socket after enucleation or evisceration. In addition to its use in anophthalmic socket surgery, Medpor is commonly used in craniofacial reconstruction surgery. Because the average pore diameter of Medpor is greater than 150 µm, which is above the standard limit (100 µm), this material allows the ingrowth of host orbital vasculature and soft tissue, which integrates the implant with the host’s body. Medpor is a firm material that is easily manufactured by heating small polyethylene spheres.1–3

Tissue ingrowth through the pores allows for biointegration, which reduces the risk of extrusion and exposure. Moreover, Medpor reduces the infection risk because the invasion of vascular structures through the pores of the orbital implant enables an immune response to infection, and antibiotics can also be delivered by systemic administration to the orbital implant.4,5 However, it is possible for an abscess to develop in the internal lacuna of Medpor, and connective tissue may erode due to the rough surface.6,7 Therefore, the most serious complications associated with integrated orbital implants after evisceration or enucleation are still exposure and infection. Although efforts have been made to reduce these complications, the reported rates vary from 0% to 21%.8–15

However, few studies have reported on the general postoperative complications after Medpor implantation in a large cohort. Alwritry et al16 reported long-term follow-up results (6 years) of porous polyethylene spherical implants after enucleation and evisceration in 106 patients, but this report placed emphasis on the superiority of operative techniques such as evisceration or enucleation, which is insufficient for a general assessment of the long-term surgical outcomes of Medpor orbital implants.

We report here on the long-term surgical outcomes of 314 patients who underwent enucleation, evisceration, or secondary orbital implantation with a porous polyethylene (Medpor) orbital implant at our hospital, and compare these outcomes with those of previously published research.

PATIENTS AND METHODS

We performed a retrospective chart review of 314 patients who underwent primary placement of a porous polyethylene orbital implant after enucleation, evisceration, or secondary implantation by an oculoplastic surgeon (SWY) at Seoul St Mary’s Hospital between 1998 and 2008. All patients provided fully informed written consent for surgery, and all patients were followed up for more than 6 months after surgery. Patient demographics, indications for the procedure, type of procedure, size of the implant placed, duration of follow-up, any complications encountered and patient management procedures were recorded. Evisceration was only performed for patients in whom evisceration was contraindicated; for example, if there was suspicion of an intraocular tumour on clinical examination or imaging study or those cases in whom it was too difficult to perform an evisceration due to severe ptosis or severe retrobulbar damage.

A 360° peritomy was performed at the limbus for enucleation, and the four quadrants were bluntly dissected to release the conjunctiva and Tenon’s capsule from the globe. The four rectus muscles were identified and isolated using muscle hooks. The muscles were cleaned of tendon and were secured with locked 5-0 polyglactin (Vicryl; Ethicon Inc., Johnson & Johnson Co., Somerville, New Jersey, USA) sutures before being detached from the globe. The dissection continued posteriorly, and the superior and inferior oblique muscles were cut. The optic nerve was transected with blunt curved scissors. The loose globe was removed, and haemostasis was secured with monopolar diathermy and pressure application. A sizing ball was used to assess the residual intraconal volume, and implant size was chosen to allow tension-free closure of the anterior ocular tissue. A porous polyethylene (Medpor) implant was left within its sterile
package, and allowed to bathe fully in 10 ml saline with 80 mg gentamicin sulphate (Gentamicin; Kukje Pharm, Seoul, Korea) for 50 min. The implant was inserted intracranially, and the rectus muscles were attached directly to the implant. Tenon’s capsule and conjunctiva were closed in layers with 6-0 polyglactin sutures (Vicryl; Ethicon Inc.).

A 360° peritomy was performed for evisceration, and an incision was made circumferentially in the sclera approximately 1–2 mm from the limbus. An evisceration spoon was used to separate the uveal tissue from the scleral shell, and the globe contents were delivered. The inside of the glove was then cleaned and debrided with a gauze swab. Anterior relaxing incisions were made in the sclera, avoiding the rectus muscles. Additional relaxing incisions were made at the equator level, respectively.

Horizontal conjunctival incisions were made during secondary implantation, and any pseudocapsule was dissected and removed. An appropriately sized Medpor orbital implant was inserted using the same method as for enucleation. The implant was inserted, and the scleral shell was closed with 5-0 polyglactin (Vicryl; Ethicon Inc.) interrupted sutures using the wrapping method. Tenon’s capsule and conjunctiva were closed in layers with 6-0 polyglactin (Vicryl; Ethicon Inc.) sutures, respectively.

After all the procedures were done, a conformer was inserted, and antibiotic ointment was placed on the ocular surface to prevent dehiscence and infection of the initial wound. The conformer was maintained for 4 weeks. Further follow-up visits were scheduled at 2, 4, 6 and 8 weeks, 6 and 12 months, and every 12 months thereafter.

The postoperative complications found during the follow-up period were classified into orbital implant, conjunctiva and lid abnormality groups, and we performed surgical or medical management according to the types and severity of the postoperative complications.

RESULTS

A total of 314 cases was identified, and the mean follow-up period was 50 months (range 6–107 months). Forty-three patients (13.7%) underwent enucleation, 229 (72.9%) underwent evisceration, and 42 (13.4%) underwent secondary orbital implantation (table 1). Trauma was the most common original cause of the need for enucleation or evisceration, accounting for 173 patients (55.2%). Glaucoma made up a large portion of the original causes for performing an evisceration rather than other procedures (14.3% vs 2.3% and 14.8% vs 9.5%). Infection or inflammation was a more common reason for performing enucleation or secondary orbital implantation instead of evisceration. Enucleation was performed in cases with a suspicious or confirmed ocular tumour (table 2).

The orbital implant size ranged from 14 to 22 mm, with the most common being an 18-mm implant (52.2%). The most common type of implant used in surgery was an orbital sphere type, the rest being either the Medpor smooth surface tunnel (SST) implant or the Medpor multipurpose conical orbital implant (MCOI) (table 3).

The most common postoperative complication was blepharoptosis (10.5%), followed by eye discharge (6.4%), implant exposure (4.5%), conjunctival contracture (4.5%), ectropion (3.5%) and implant infection (1%) in a total of 314 patients. The overall postoperative complication incidences were 72.1% (31/43) in patients who received enucleation, 27.1% (62/229) in patients who received evisceration and 59.5% (25/42) in patients who received secondary orbital implantation. The most common postoperative complication was blepharoptosis in all three groups (table 4).

All three patients with an implant infection underwent implant exchange. Staphylococcus aureus was cultured in two cases, and Streptococcus epidermidis was cultured in one case (table 5). All 14 cases of implant exposure were significant in size, which required operative intervention with an allogenic graft or sclera. Four patients (28.6%) who received enucleation, eight patients (57.1%) who received evisceration and two patients (14.3%) who received secondary orbital implantation were included in these 14 cases. After this surgical intervention, two cases of implant exposure recurred. One of these cases underwent an implant exchange, and the other case underwent implant removal (table 6). The four cases of giant papillary conjunctivitis were recovered with conservative care, and removal was performed in two cases of conjunctival cyst and granuloma. Nine cases of fornix contracture (9/14, 64.3%)...

### Table 1 Patient demographics

| Characteristic          | Enucleation (N = 43) | Evisceration (N = 229) | Secondary orbital implantation (N = 42) | Total (N = 314) |
|-------------------------|----------------------|------------------------|----------------------------------------|-----------------|
| Age, years (range)      | 46.81 (2–78)         | 51.54 (2–87)           | 47.25 (1–77)                           | 50.35 (1–87)    |
| Gender (M:F)            | 19:24                | 112:117                | 20:22                                  | 151:163         |
| Follow-up, months (range)| 44 (6–92)           | 46 (6–107)             | 58 (6–87)                              | 50 (6–107)      |

N, number of patients.

### Table 2 Original causes for anophthalmic surgery

| Cause                          | Enucleation (N = 43) | Evisceration (N = 229) | Secondary orbital implantation (N = 42) | Total (N = 314) |
|-------------------------------|----------------------|------------------------|----------------------------------------|-----------------|
| Trauma (%)                    | 21 (48.8%)           | 132 (57.6%)            | 20 (47.6%)                             | 173 (55.2%)     |
| Glaucoma (%)                  | 1 (2.3%)             | 34 (14.8%)             | 4 (9.5%)                               | 39 (12.4%)      |
| Corneal ulcer (%)             | 3 (7.0%)             | 29 (12.7%)             | 4 (9.5%)                               | 36 (11.5%)      |
| Ocular inflammation/infection% | 9 (21.0%)            | 14 (6.1%)              | 6 (14.4%)                              | 29 (9.2%)       |
| Tumours (%)                   | 8 (18.6%)            | 0 (0%)                 | 4 (9.5%)                               | 12 (3.8%)       |
| Others (%)                    | 1 (2.3%)             | 20 (8.8%)              | 4 (9.5%)                               | 25 (7.9%)       |

N, number of patients.
received reconstruction with oral mucosa and dermis, and five cases (5/14, 55.7%) received reconstruction with alloderm (Surederm; Hans Biomed Co, Seoul, Korea). Three cases (3/4, 75.0%) of wound dehiscence, which were small and caused by an inapproxiated conjunctival suture, required only conservative management, but one case (1/4, 25.0%) received an additional suture. Most of the complications associated with lid problems (59/54, 72.2%) required operative management. For the blepharoptosis (n=33) and dermatochalasis cases (n=5), 18 patients (18/36, 50.0%) received a blepharoplasty, 10 (10/36, 27.8%) received a levator resection and three (3/36, 8.3%) received levator advancement. Three patients who had a deep upper lid sulcus received silastic sheet insertion on the superior orbital wall via the skin incision. Three patients who had lower lid entropion received lower lid retractor re-insertion, and two patients received Quickert suture. Ocular pain or eye discharge was treated with conservative care, and these patients recovered.

We did not routinely use a motility coupling post (MCP) because most patients who had undergone anophthalmic surgery and obtained a sufficient conjunctival fold showed good movement without a MCP. Only 52 patients received a MCP insertion, five needed a position correction, and two underwent re-insertion due to failure. No infection was observed in the patients who received a MCP insertion (table 7).

**DISCUSSION**

Polyethylene is a high-density, straight-chain hydrocarbon formed by polymerisation of ethylene molecules under high temperature and pressure. Medpor is a polyporous form (150–400 μm) of polyethylene that is manufactured by heating and compacting polyethylene granules into spherical shapes of different size. This porous character enables fibrovascular proliferation of orbital tissue, reduces the risk of migration, exposure and extrusion, and minimises the risk of infection. This material is also non-toxic, non-allergenic and highly biocompatible. It is not brittle, thus allowing muscles to be sutured directly to it with no need for sclera.4 Many studies have reported favourable surgical outcomes after Medpor orbital implantation.11–22

Medpor has a rough surface, which tends to cause erosion of Tenon’s capsule and conjunctiva and eventually implant exposure. To compensate for this defect, other types of Medpor have been introduced. Medpor SST is a further refinement of the original polyporous polyethylene (Medpor). It has a smooth, porous anterior surface, which helps minimise late-implant exposures, and the suture tunnels allow for easy attachment of the rectus muscle without the use of an implant wrap. Medpor MCOI is cone-shaped, which makes it possible to provide additional volume in the orbit with a similar diameter implant. Medpor MCOI has more utility in patients with severe ptosis bulbi. Medpor is currently a very popular polyporous orbital implant material. The other orbital implant materials include hydroxyapatite and aluminum oxide.

However, unlike hydroxyapatite implants, only relatively small case series have been published on the exposure and complication rates of Medpor orbital implants. Karciglo et al23 reported eight cases of conjunctival dehiscence exposure, five cases of fornix contracture and three cases of inappropriate volume replacement in 37 patients who underwent enucleation and Medpor orbital implantation due to retinoblastoma. Cheng et al24 reported that implant exposure occurred in up to one-third of patients who received Medpor orbital implantation over a 2-year follow-up period, and this was particularly common after MCP insertion. Shaamanesh et al25 reported postoperative complications in 52 patients who had received Medpor implants with a 14-year follow-up period. Baek26 reported five cases of implant exposure and four cases of superior sulcus deformity in 56 patients after evisceration, enucleation, or secondary orbital implantation during 2 years of follow-up. We studied the overall postoperative outcomes in 314 patients over 10 years of follow-up.

Our study showed only a 1% (3/314) incidence rate of Medpor orbital implant infection, and these three cases required an
Implant exchange. This rate is similar to the infection rate of the hydroxyapatite orbital implant, which ranges from 0% to 1.5%.26,27 Postoperative implant infection using Medpor is rare, limited to only a few case reports,52,82,9 probably because Medpor has a hydrophobic and negatively charged surface that acts as a protective envelope to inhibit the adherence of bacteria.28

In the present study, implant exposure occurred in 9.3% of patients who underwent enucleation and in 3.5% of patients who underwent evisceration. Alwitry et al16 reported the long-term follow-up surgical outcomes (6 years) of 106 patients who underwent spherical Medpor implantation, and reported that the implant exposure rate was 6.3% (5/80) for patients who underwent enucleation and 53.8% (14/26) for patients who underwent evisceration. The original reason for the surgery was different between the study of Alwitry et al16 and our study. The most common cause of anophthalmic surgery was trauma in both studies, but its frequency was different: approximately 30% in our study and up to 50% in the study by Alwitry et al16. In both studies, the surrounding tissue around the eyeball was damaged by trauma, and the degree of damage affected recovery rate and the final surgical outcome. Therefore, a simple comparison of incidence rates between the two studies has no meaning. In addition, we included data on patients who received Medpor MCOI and Medpor SST, not just the spherical Medpor, which may have influenced our results, whereas the study by Alwitry et al16 only included data on patients who received the spherical Medpor.

The results showed similar postoperative complication rates, except the rate of fornix contracture between the patients who had received enucleation (6/45, 14.0%) and secondary orbital implantation (1/42, 2.4%). This result was caused by the fact that secondary orbital implantation was mostly considered when an unfit artificial eye was detected.

Yoon et al26 reported that the rate of orbital implant exposure in 802 patients who received hydroxyapatite orbital implantation with a 15-year follow-up was 2.1%. Shoamanesh et al25

### Table 6: Postoperative orbital implant exposure

| No | Gender/age (years) | Preoperative diagnosis | Type of previous surgery | Size of implant (mm) | MCP insertion | Complication-free follow-up period (months) | Recurrence after management using sclera or allograft |
|----|--------------------|------------------------|--------------------------|---------------------|--------------|---------------------------------------------|-------------------------------------------------|
| 1  | M/66               | Trauma                 | Enucleation              | 20                  | None         | 20                                          | None                                            |
| 2  | M/46               | Tumour                 | Enucleation              | 18                  | Yes          | 27                                          | None                                            |
| 3  | F/60               | Ocular infection       | Enucleation              | 18                  | None         | 30                                          | None                                            |
| 4  | M/49               | Trauma                 | Enucleation              | 20                  | None         | 47                                          | None                                            |
| 5  | F/38               | Trauma                 | Enucleation              | 20                  | None         | 61                                          | None                                            |
| 6  | M/55               | Trauma                 | Evisceration             | 20                  | None         | 14                                          | Yes (implant exchange)                          |
| 7  | F/44               | Trauma                 | Evisceration             | 18                  | None         | 26                                          | None                                            |
| 8  | M/43               | Trauma                 | Evisceration             | 18                  | None         | 38                                          | None                                            |
| 9  | M/75               | Phthisis bulbi         | Evisceration             | 20                  | None         | 55                                          | None                                            |
| 10 | F/68               | Glaucoma               | Evisceration             | 20                  | None         | 29                                          | None                                            |
| 11 | F/73               | Phthisis bulbi         | Evisceration             | 20                  | None         | 35                                          | None                                            |
| 12 | M/39               | Trauma                 | Evisceration             | 20                  | None         | 24                                          | None                                            |
| 13 | F/50               | Glaucoma               | Secondary orbital implantation | 18         | None         | 18                                          | Yes (implant removal)                           |
| 14 | M/59               | Trauma                 | Secondary orbital implantation | 18         | None         | 38                                          | None                                            |

MCP, motility coupling post.

### Table 7: Patients with a MCP

| Type of operation                       | No of patients |
|-----------------------------------------|----------------|
| Enucleation                             | 14 (3: recorrection, 2: succeeded after a failure) |
| Evisceration                            | 13 (2: recorrection) |
| Secondary orbital implantation          | 5              |
| Total                                   | 32             |

MCP, motility coupling post.

Implant exchange. This rate is similar to the infection rate of the hydroxyapatite orbital implant, which ranges from 0% to 1.5%.26,27 Postoperative implant infection using Medpor is rare, limited to only a few case reports,52,82,9 probably because Medpor has a hydrophobic and negatively charged surface that acts as a protective envelope to inhibit the adherence of bacteria.28

In the present study, implant exposure occurred in 9.3% of patients who underwent enucleation and in 3.5% of patients who underwent evisceration. Alwitry et al16 reported the long-term follow-up surgical outcomes (6 years) of 106 patients who underwent spherical Medpor implantation, and reported that the implant exposure rate was 6.3% (5/80) for patients who underwent enucleation and 53.8% (14/26) for patients who underwent evisceration. The original reason for the surgery was different between the study of Alwitry et al16 and our study. The most common cause of anophthalmic surgery was trauma in both studies, but its frequency was different: approximately 30% in our study and up to 50% in the study by Alwitry et al16. In both studies, the surrounding tissue around the eyeball was damaged by trauma, and the degree of damage affected recovery rate and the final surgical outcome. Therefore, a simple comparison of incidence rates between the two studies has no meaning. In addition, we included data on patients who received Medpor MCOI and Medpor SST, not just the spherical Medpor, which may have influenced our results, whereas the study by Alwitry et al16 only included data on patients who received the spherical Medpor.

The results showed similar postoperative complication rates, except the rate of fornix contracture between the patients who had received enucleation (6/45, 14.0%) and secondary orbital implantation (1/42, 2.4%). This result was caused by the fact that secondary orbital implantation was mostly considered when an unfit artificial eye was detected.

Yoon et al26 reported that the rate of orbital implant exposure in 802 patients who received hydroxyapatite orbital implantation with a 15-year follow-up was 2.1%. Shoamanesh et al25

### Table 8: Summary of the major studies on porous orbital implants

| Complications         | Material | Our study (N = 314) | Alwitry et al16 (N = 106) | Shoamanesh et al15 (N = 32) | Blaydon et al18 (N = 136) | Yoon et al15 (N = 802) |
|-----------------------|----------|---------------------|---------------------------|-----------------------------|---------------------------|-----------------------|
| Implants              | Infection| 3                   | 14                        | 19                         | 19                        | 10                    |
|                       | Exposure | 14                  | 19                        | 2                          | 5                         | 0                     |
| Conjunctiva           | Giant papillary conjunctivitis | 4 | 1 | 2 | 6 | 2 |
|                       | Conjunctival cyst/granuloma | 1 | 2 | 2 | 6 | 2 |
|                       | Fornix contracture | 14 | 3 | 3 | 1 | 28 |
|                       | Wound dehiscence | 4 | 4 | 4 | 4 | 38 |
| Eyelid                | Blepharoptosis | 33 | 9 | 9 | 9 | 9 |
|                       | Dermatochalasis | 3 | 3 | 3 | 3 | 3 |
|                       | Deep upper lid sulcus | 7 | 7 | 7 | 7 | 7 |
|                       | Entropion | 11 | 11 | 11 | 11 | 11 |
| Others                | Pain/discomfort (>6 weeks) | 3 | 3 | 3 | 3 | 3 |
|                       | Discharge (>6 weeks) | 20 | 20 | 20 | 20 | 20 |

N, number of patients.
found that the rate of exposure was 6% for 432 patients who underwent hydroxyapatite orbital implantation and 6.25% for 52 patients who underwent Medpor orbital implantation. Back et al. reported a rate of exposure of 13% for 56 eyes that underwent Medpor orbital implantation; however, all 56 eyes successfully recovered with a dermograft. Custer and Trinkaus reported that the exposure rates were similar between hydroxyapatite (5.1%) and Medpor (4.2%) when patients with retinoblastoma were omitted from the pooled data in a meta-analysis of porous orbital implant studies. These reports show that surgical outcomes vary according to factors such as operator technique and the status of the conjunctiva around the operation site. More studies may be needed to determine conclusively whether hydroxyapatite or Medpor is superior, because few studies have focused on patients who received Medpor orbital implants.

Other postoperative complications may also occur, including conjunctival abnormalities and lid problems. Yoon et al. reported that conjunctival cysts and conjunctival wound dehiscence occurred in 0.2% and 5.5% of patients who received hydroxyapatite orbital implantation, respectively, but they did not receive pegging. No marked differences were observed between the study of Yoon et al. and our study, which showed rates of 0.6% and 1.3% for conjunctival cysts and conjunctival wound dehiscence, respectively. Shaomanesh et al. found that blepharoptosis occurred in 20.1% of patients who underwent Medpor orbital implantation, and this was the most common postoperative complication. Our study showed similar results; blepharoptosis was the most common postoperative problem, and its incidence rate was 10.5%. However, most cases of blepharoptosis successfully recovered after a blepharoplasty or other corrective operation (table 8).

MCP insertion was performed in 10.2% of the patients at our institute, which is a relatively low rate, and most underwent this procedure before 2002. MCP has been used to improve artificial eyes, but it may increase the infection rate of an orbital implant. Furthermore, unskilled insertion of an MCP requires repositioning or removal and re-insertion. Therefore, we do not typically perform MCP insertion if the motility of an artificial eye is satisfactory and the patient does not wish to do it.

In summary, we report a large case series of patients implanted with porous polyethylene orbital implants with an extended follow-up. We highlighted the previously undocumented general postoperative complications after Medpor orbital implantation during long-term follow-up, and no marked differences in the complications between hydroxyapatite and Medpor were observed. We also successfully resolved the postoperative complications associated with Medpor. Therefore, we suggest that Medpor produces tolerable surgical outcomes as an orbital implant because of lower material cost, convenience of the operative procedure and other advantages.

Competing interests None.

Patient consent Obtained.

Ethics approval Ethics approval was provided by the Catholic Medical Centre clinical research coordinating centre.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. Lee S, Maronian N, Most SP, et al. Porous high-density polyethylene for orbital reconstruction. Arch Otolaryngol Head Neck Surg 2005;131:466–50.
2. Klawitter JJ, Bagwell JS, Weinstein AM, et al. An evaluation of bone growth into porous high density polyethylene. J Biomed Mater Res 1976;10:311–23.
3. Specter M, Remming WR, Sauer BW. Early tissue infiltrate in porous polyethylene implants into bone: a scanning electron microscope study. J Biomed Mater Res 1975;9:537–42.
4. Hornblass A, Biesman BS, Eviatar JA. Current techniques of enucleation: a survey of 5,439 intraorbital implants and a review of the literature. Ophthalmol Plast Reconstr Surg 1995;11:77–86.
5. Lee JH, Choi WC. A case of Medpor® orbital implant infection. J Korean Ophthalmol Soc 2001;42:783–7.
6. Jordan DR, Brownstein S, Jolly SS. Abscessed hydroxyapatite orbital implants. A report of two cases. Ophthalmol 1996;103:1784–7.
7. Kurcioglu ZA. Actinomycosis infection in porous polyethylene orbital implant. Graefes Arch Clin Exp Ophthalmol 1997;235:448–51.
8. Blaydon AM, Shepler TR, Neuhaus RW, et al. The porous polyethylene (Medpor) spherical orbital implant. Ophthal Plast Reconstr Surg 2003;19:368–71.
9. McBath A. Hydroxyapatite orbital implants: experience with 100 cases. Aust NZ J Ophthalmol 1995;23:117–23.
10. Oestreicher JH, Liu E, Berkowitz M. Complications of hydroxyapatite orbital implants: a review of 100 consecutive cases and a comparison of Devon mesh (polyglycolic acid) and scleral wrapping. Ophthalmol 1997;104:324–9.
11. Beutnner H, Bartley GB. Tissue breakdown and exposure associated with orbital hydroxyapatite implants. Am J Ophthalmol 1992;113:869–73.
12. Nunery WR, Heinz GW, Bonnin JM, et al. Exposure rate of hydroxyapatite spheres in the anophthalmic socket: histopathological correlation and comparison with silicone sphere implants. Ophthal Plast Reconstr Surg 1993;9:96–104.
13. Remulla ND, Rubin PA, Shore JW, et al. Complications of porous spherical implants. Ophthalmol 1995;102:586–93.
14. Kostick DA, Linberg JV. Evisceration with hydroxyapatite implant: surgical technique and review of 31 case reports. Ophthalmol 1995;102:1542–8.
15. Yang JG, Khwarg SI, Wee WR, et al. Hydroxyapatite implantation with scleral quadrisection after enucleation. Ophthal Surg Lasers 1997;28:915–19.
16. Ahlwyty A, West S, King J, et al. Long-term follow-up of porous polyethylene spherical implants after enucleation and evisceration. Ophthal Plast Reconstr Surg 2007;23:11–15.
17. Baek SH. Clinical effect of porous polyethylene (Medpor®) orbital implant. J Korean Ophthalmol Soc 2000;41:1584–63.
18. Blaydon SM, Shepler TR, Neuhaus RW, et al. The porous polyethylene (Medpor®) spherical orbital implant: a retrospective study of 136 cases. Ophthal Plast Reconstr Surg 2003;19:364–71.
19. Koh YM, Na KS. Comparison of clinical results between hydroxyapatite and Medpor orbital implant. J Korean Ophthalmol Soc 2002;43:349–56.
20. Tang CK, Lee DW, Rho SH, et al. Long-term results of hydroxyapatite and Medpor orbital implant. J Korean Ophthalmol Soc 2004;45:1239–49.
21. Choi AH, Woog JJ, Kim YD, Medpor® S571TM Enucleation Implant. J Korean Ophthalmol Soc 2003;44:773–9.
22. Koh YM, Na KS. Comparison of clinical results between hydroxyapatite and Medpor orbital implant. J Korean Ophthalmol Soc 2002;43:349–56.
23. Kostick DA, Linberg JV. Evisceration with hydroxyapatite implant: surgical technique and review of 31 case reports. Ophthalmol 1995;102:1542–8.
24. Yang JG, Khwarg SI, Wee WR, et al. Hydroxyapatite implantation with scleral quadrisection after enucleation. Ophthal Surg Lasers 1997;28:915–19.
25. Ahlwyty A, West S, King J, et al. Long-term follow-up of porous polyethylene spherical implants after enucleation and evisceration. Ophthal Plast Reconstr Surg 2007;23:11–15.
26. Baek SH. Clinical effect of porous polyethylene (Medpor®) orbital implant. J Korean Ophthalmol Soc 2000;41:1584–63.
27. Blaydon SM, Shepler TR, Neuhaus RW, et al. The porous polyethylene (Medpor®) spherical orbital implant: a retrospective study of 136 cases. Ophthal Plast Reconstr Surg 2003;19:364–71.
28. Koh YM, Na KS. Comparison of clinical results between hydroxyapatite and Medpor orbital implant. J Korean Ophthalmol Soc 2002;43:349–56.
29. Tang CK, Lee DW, Rho SH, et al. Long-term results of hydroxyapatite and Medpor orbital implant. J Korean Ophthalmol Soc 2004;45:1239–49.
30. Choi AH, Woog JJ, Kim YD, Medpor® S571TM Enucleation Implant. J Korean Ophthalmol Soc 2003;44:773–9.
31. Kostick DA, Linberg JV. Evisceration with hydroxyapatite implant: surgical technique and review of 31 case reports. Ophthalmol 1995;102:1542–8.
32. Yang JG, Khwarg SI, Wee WR, et al. Hydroxyapatite implantation with scleral quadrisection after enucleation. Ophthal Surg Lasers 1997;28:915–19.
33. Ahlwyty A, West S, King J, et al. Long-term follow-up of porous polyethylene spherical implants after enucleation and evisceration. Ophthal Plast Reconstr Surg 2007;23:11–15.
34. Baek SH. Clinical effect of porous polyethylene (Medpor®) orbital implant. J Korean Ophthalmol Soc 2000;41:1584–63.
35. Blaydon SM, Shepler TR, Neuhaus RW, et al. The porous polyethylene (Medpor®) spherical orbital implant: a retrospective study of 136 cases. Ophthal Plast Reconstr Surg 2003;19:364–71.
36. Koh YM, Na KS. Comparison of clinical results between hydroxyapatite and Medpor orbital implant. J Korean Ophthalmol Soc 2002;43:349–56.
37. Tang CK, Lee DW, Rho SH, et al. Long-term results of hydroxyapatite and Medpor orbital implant. J Korean Ophthalmol Soc 2004;45:1239–49.
38. Choi AH, Woog JJ, Kim YD, Medpor® S571TM Enucleation Implant. J Korean Ophthalmol Soc 2003;44:773–9.